The federal pilot that allows selected digital health devices to reach Medicare patients before the Food and Drug Administration has reviewed them now includes an artificial intelligence voice agent that delivers structured psychological therapy. It is one of four products on the list, and it marks the point where the program moved from monitoring blood sugar and blood pressure into mental health treatment.
The device, called Unpacked and made by Limbic Inc., is intended for use within a structured outpatient behavioral health service model to deliver cognitive behavioral therapy to Medicare beneficiaries with clinically significant depression or anxiety through an AI voice agent. A second behavioral health product, SonderMind's adjunctive care application, is also on the list.
The FDA states plainly on its own participant page that the effectiveness of these devices, for the intended uses under which they are participating, has not yet been evaluated by the agency. For patients and families, that sentence is the whole story.
Four Participants Now, Two of Them in Behavioral Health
The Technology-Enabled Meaningful Patient Outcomes pilot, known as TEMPO, was created alongside a Medicare payment model run by the CMS Innovation Center called Advancing Chronic Care with Effective, Scalable Solutions, or ACCESS. Each manufacturer selected for TEMPO intends to offer a device for use in care expected to be covered by that model.
MedicalDaily reported when the FDA named its first participant, a continuous glucose monitoring program, and again when hypertension management software became the second. Those products addressed measurable physiological targets in cardio-kidney-metabolic care.
The current participant list names four manufacturers: SonderMind, Limbic, Cadence Solutions, and Dexcom. Half of them now sit in behavioral health, a category where outcomes are self-reported, where the therapeutic relationship itself is part of the treatment, and where the consequences of a wrong response are harder to measure than a blood pressure reading.
The Contraindication List Runs Longer Than the Indication
The most revealing part of the FDA's entry for the AI voice therapy product is not what it treats but who it must not treat. The contraindication list is by far the longest on the page.
Unpacked is contraindicated for people with suicidal or homicidal ideation, moderate to severe dementia or severe cognitive impairment, any psychiatric disorder with distinct psychotic features, active severe self-harm without suicidal intent, complex disorders without psychotic features such as bipolar II disorder and personality disorders, substance use disorder as a primary condition or risk of dangerous intoxication or withdrawal, eating disorders of any severity, acute physical health instability, and pregnancy. It also excludes patients 81 and older with a frailty indication, those receiving hospice or palliative care, patients 66 and older entering long-term nursing home care during the intervention window, and people who do not speak or read English or who lack access to a telephone.
That list is a reasonable safety design. It is also a description of conditions that commonly accompany depression and anxiety in older adults, which is the population the Medicare model serves. Screening people into and out of the device correctly becomes a clinical task of its own.
The FDA's description of the device includes real-time safety flagging, measurement-based care, and support for clinical oversight. The pilot is not describing an unsupervised chatbot.
Enforcement Discretion Is Not Approval
The regulatory mechanism deserves plain language. Under TEMPO, the FDA says it intends to exercise enforcement discretion for certain requirements, such as premarket authorization and investigational device requirements, when a participating manufacturer's device is offered to or by ACCESS participants for the listed intended use.
Enforcement discretion means the agency is choosing not to enforce rules that would otherwise apply. It is not clearance, not approval, and not a finding that a device works. In exchange, manufacturers collect, monitor, and report real-world data relating to those intended uses.
The agency framed the program at its launch as a first-of-its-kind effort to expand access to chronic disease technologies while safeguarding patient safety, and it describes TEMPO as intended to promote access to certain digital health devices. More on how companies are chosen appears on the pilot's own page.
The rationale is coherent. Software changes faster than a fixed review process can track, and a device can be materially different by the time a review concludes. The trade is that patients become part of the evidence-generating process rather than the beneficiaries of evidence already generated.
Patients May Not Know a Device Is Unreviewed
The gap this raises for households is one of disclosure. A Medicare beneficiary offered a digital therapy program through their care team has no obvious way to know that the underlying device is operating under enforcement discretion rather than authorization. Nothing in the public participant materials specifies what patients are told, or in what terms.
Anyone offered a digital health program through a Medicare care model can reasonably ask three questions. Is this device FDA-authorized for this use, or is it in a pilot? Which clinician is responsible for my care and how do I reach them. And what happens to the data collected about me.
Patients in mental health treatment should not stop, change, or substitute care based on this article. Anyone in crisis should contact a clinician or call or text 988 to reach the Suicide and Crisis Lifeline. The pilot's terms describe these tools as sitting alongside clinical care rather than replacing it.
The FDA says it intends to update its participant table as additional manufacturers are selected. That table, rather than any company announcement, is the authoritative record of what is in the program.
Key Questions Answered
What changed in the TEMPO pilot? The participant list has grown to four devices and now includes two behavioral health products, one of which delivers cognitive behavioral therapy through an AI voice agent.
Does the FDA say these devices work? No. The agency states on its participant page that the effectiveness of the selected devices, for the intended uses under which they are participating, has not yet been evaluated.
What does enforcement discretion mean? The FDA is choosing not to enforce certain requirements, such as premarket authorization, while participating devices are offered within the Medicare ACCESS model. It is not approval or clearance.
Is a human clinician involved? Yes. The FDA description includes clinical oversight, real-time safety flagging, and outcome monitoring. These are not described as unsupervised tools.
Who is excluded from the AI therapy device? The contraindication list includes suicidal or homicidal ideation, psychotic disorders, moderate to severe dementia, eating disorders, primary substance use disorder, pregnancy, and people without telephone access.
How would a patient know a device is in the pilot? Public participant materials do not specify what patients are told. Anyone offered a digital health program through Medicare can ask whether the device is FDA-authorized or in a pilot.
Where can someone in crisis get help? Call or text 988 to reach the Suicide and Crisis Lifeline, or contact a clinician directly. Do not stop or change mental health treatment without speaking with a health care professional.
